Anaplastic lymphoma kinase: Role in cancer and therapy perspective

Zhihong Zhao, Vivek Verma, Mutian Zhang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal fusion of ALK or non-fusion ALK activation. ALK is a receptor tyrosine kinase, with a single transmembrane domain, that plays an important role in development. Upon ligand binding to the extracellular domain, the receptor undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. In recent years, ALK inhibitors have been developed for cancer treatment. These inhibitors target ALK activity and show effectiveness in ALK-positive non-small cell lung cancer. However, acquired treatment resistance makes the future of this therapy unclear; new strategies are underway to overcome the limitations of current ALK inhibitors.

Original languageEnglish (US)
Pages (from-to)1691-1701
Number of pages11
JournalCancer Biology and Therapy
Volume16
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

Neoplasms
Therapeutics
Anaplastic Large-Cell Lymphoma
anaplastic lymphoma kinase
Receptor Protein-Tyrosine Kinases
Dimerization
Neuroblastoma
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Carcinogenesis
Phosphotransferases
Breast Neoplasms
Ligands

Keywords

  • anaplastic lymphoma kinase
  • cancer
  • inhibitor
  • resistance
  • therapy
  • tyrosine kinase

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Anaplastic lymphoma kinase : Role in cancer and therapy perspective. / Zhao, Zhihong; Verma, Vivek; Zhang, Mutian.

In: Cancer Biology and Therapy, Vol. 16, No. 12, 02.12.2015, p. 1691-1701.

Research output: Contribution to journalArticle

Zhao, Zhihong ; Verma, Vivek ; Zhang, Mutian. / Anaplastic lymphoma kinase : Role in cancer and therapy perspective. In: Cancer Biology and Therapy. 2015 ; Vol. 16, No. 12. pp. 1691-1701.
@article{886007484ae84c098d9b2637e3f8a15f,
title = "Anaplastic lymphoma kinase: Role in cancer and therapy perspective",
abstract = "Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal fusion of ALK or non-fusion ALK activation. ALK is a receptor tyrosine kinase, with a single transmembrane domain, that plays an important role in development. Upon ligand binding to the extracellular domain, the receptor undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. In recent years, ALK inhibitors have been developed for cancer treatment. These inhibitors target ALK activity and show effectiveness in ALK-positive non-small cell lung cancer. However, acquired treatment resistance makes the future of this therapy unclear; new strategies are underway to overcome the limitations of current ALK inhibitors.",
keywords = "anaplastic lymphoma kinase, cancer, inhibitor, resistance, therapy, tyrosine kinase",
author = "Zhihong Zhao and Vivek Verma and Mutian Zhang",
year = "2015",
month = "12",
day = "2",
doi = "10.1080/15384047.2015.1095407",
language = "English (US)",
volume = "16",
pages = "1691--1701",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - Anaplastic lymphoma kinase

T2 - Role in cancer and therapy perspective

AU - Zhao, Zhihong

AU - Verma, Vivek

AU - Zhang, Mutian

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal fusion of ALK or non-fusion ALK activation. ALK is a receptor tyrosine kinase, with a single transmembrane domain, that plays an important role in development. Upon ligand binding to the extracellular domain, the receptor undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. In recent years, ALK inhibitors have been developed for cancer treatment. These inhibitors target ALK activity and show effectiveness in ALK-positive non-small cell lung cancer. However, acquired treatment resistance makes the future of this therapy unclear; new strategies are underway to overcome the limitations of current ALK inhibitors.

AB - Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal fusion of ALK or non-fusion ALK activation. ALK is a receptor tyrosine kinase, with a single transmembrane domain, that plays an important role in development. Upon ligand binding to the extracellular domain, the receptor undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. In recent years, ALK inhibitors have been developed for cancer treatment. These inhibitors target ALK activity and show effectiveness in ALK-positive non-small cell lung cancer. However, acquired treatment resistance makes the future of this therapy unclear; new strategies are underway to overcome the limitations of current ALK inhibitors.

KW - anaplastic lymphoma kinase

KW - cancer

KW - inhibitor

KW - resistance

KW - therapy

KW - tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=84954554286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954554286&partnerID=8YFLogxK

U2 - 10.1080/15384047.2015.1095407

DO - 10.1080/15384047.2015.1095407

M3 - Article

C2 - 26529396

AN - SCOPUS:84954554286

VL - 16

SP - 1691

EP - 1701

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 12

ER -